Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy

Published:2013-05-29 Issue:16 Volume:119 Page:3012-3019
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Galsky Matthew D.¹,Moshier Erin²,Krege Susan³,Lin Chia-Chi⁴,Hahn Noah⁵,Ecke Thorsten⁶,Sonpavde Guru⁷⁸,Godbold James²,Oh William K.¹,Bamias Aristotle⁹

Affiliation:

1. Division of Hematology and Medical Oncology; The Tisch Cancer Institute, Mount Sinai School of Medicine; New York New York

2. Department of Preventive Medicine; Mount Sinai School of Medicine; New York New York

3. Urological Clinic, Alexianer Krefeld GmbH; Krefeld Germany

4. Department of Oncology; National Taiwan University Hospital; Taipei Taiwan

5. Division of Hematology and Oncology; Department of Medicine; Indiana University Melvin and Bren Simon Cancer Center; Indianapolis Indiana

6. Department of Urology; HELIOS Hospital; Bad Saarow Germany

7. US Oncology Research; LLC, McKesson Specialty Health; The Woodlands Texas

8. Texas Oncology; Webster Texas

9. Department of Therapeutics; University of Athens Medical School, Hellenic Cooperative Oncology Group; Athens Greece

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.28146/fullpdf

Reference32 articles.

1. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours;Sternberg;Eur J Cancer.,2006

2. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study;Maase;J Clin Oncol.,2000

3. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer;Maase;J Clin Oncol.,2005

4. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy;Bajorin;J Clin Oncol.,1999

5. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine;Bellmunt;Cancer.,2002

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Podcast on Practical Considerations in Patients with Advanced Urothelial Cancer Receiving First-Line Cisplatin- or Carboplatin-Based Chemotherapy Followed by Avelumab Maintenance in a Changing Therapeutic Landscape;Advances in Therapy;2024-07-18

2. Outcome Prediction Using Multi-Modal Information: Integrating Large Language Model-Extracted Clinical Information and Image Analysis;Cancers;2024-06-29

3. Geriatric nutritional risk index and controller nutritional status score before metastatic first-line chemotherapy predict survival in patients over 70 years of age with metastatic bladder cancer;Frontiers in Medicine;2024-05-10

4. Pre-first-line chemotherapy risk stratification for overall survival in advanced urothelial carcinoma in sequential therapy era;World Journal of Urology;2024-05-09

5. Efficacy of cytoreductive radical cystectomy in metastatic urothelial bladder cancer based on site and number of metastases;Urologic Oncology: Seminars and Original Investigations;2024-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3